Key stakeholders
These are the current top-level decision-makers at the company and their LinkedIn profiles. Check them for recent activity and updates
Latest news about Abbott Laboratories
Here are some of the most recent media mentions. Use them in your sales prospecting to qualify a prospect's buyer intent and personalize outreach with the latest company updates
Abbott Laboratories reported third-quarter 2024 results with $10.6 billion in sales, driven by strong underlying base business performance and double-digit growth in Medical Devices. Organic sales growth, excluding COVID-19 testing, was 8.2%, and full-year organic sales growth guidance remains at 9.5% to 10.0%. Adjusted diluted EPS guidance was raised to $4.64 to $4.70[2][4][5].
Abbott's board of directors authorized a new share repurchase program of up to $7 billion of the company's common shares in October 2024. Additionally, Abbott announced a global partnership with Medtronic to integrate its continuous glucose monitoring system with Medtronic's insulin delivery devices and launched Lingo™, a prescription-free continuous glucose monitoring system, in the U.S. in September 2024[3].
Abbott Laboratories declared its 403rd consecutive quarterly dividend in September 2024, highlighting the company's consistent commitment to shareholder value. Additionally, Abbott initiated a clinical study in August 2024 to evaluate the use of its deep brain stimulation system to manage severe depression[3].
Open job positions at Abbott Laboratories
This company is actively hiring to fill these roles. Use this for sales prospecting if your solution assists, augments, or provides an alternative for the growing team and position.